Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke
prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial …

Abstract Background Oral anticoagulants (OACs) mitigate stroke risk in patients with atrial
fibrillation (AF). The study aim was to analyze prevalence and predictors of OAC …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …

Background Large-scale investigations on the use of oral anticoagulants including direct
oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) have not included …

Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF)
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …

Purpose To study whether polypharmacy or drug–drug interactions have differential effect
on safety and efficacy in patients treated with direct oral anticoagulants (DOACs) versus …

Atrial fibrillation (AF) is a common cardiovascular disease for which newer oral
anticoagulants are available. The main objective of this study was to evaluate the …

Objective To determine the association between direct oral anticoagulant (DOAC) use and
risk of major adverse cardiac events (MACEs) in patients with atrial fibrillation (AF). Patients …

Background: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia.
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …

Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …